What to Expect at the 7th Glioblastoma Drug Development Summit - the Leading Forum for Glioblastoma Drug Development
No matter where you are in your journey, whether you’re pioneering a new modality or scaling innovation, the 7th Glioblastoma Drug Development Summit is a mission to bring hope to patients and families facing one of the most aggressive brain cancers.
Recent breakthroughs, like Mustang Bio’s orphan drug designation for its CAR-T therapy and SurVaxM’s promising Phase IIb results, have reignited optimism in glioblastoma research. This summit is where that momentum becomes action and science meets compassion to accelerate life-changing therapies.
Together, we’ll tackle the questions that matter most for patients:
- How can AI, multiomics, and molecular subtyping help us identify the right treatment for the right patients faster?
- What role do K9 models, patient-derived organoids, and engineered rodent models play in building safer, more effective therapies?
- Which innovative approaches like gene therapies, cancer vaccines, CAR-T, ADCs hold the greatest promise for extending and improving lives?
- How do we design trials that prioritize patient well-being, eliminating placebo arms for those who cannot afford to wait?
- What strategies will unlock the funding and partnerships needed to bring these therapies from bench to bedside?
This summit represents more than a scientific forum, it is a collective call to action for all stakeholders dedicated to transforming the future of glioblastoma care. Behind every data point lies a patient, a family, and a story, underscoring the urgency and responsibility we share to deliver meaningful progress.
Overcoming the Brain’s Immunosuppressive Environments with Cell Therapy Approaches for Breakthrough GBM Treatments
Following Kite Pharma and Gilead’s impressive breakthrough in a CAR-T treatment for Glioblastoma, cell therapy approaches are becoming a new source oh hope for the GBM field. This session will see data from Kite/Gileads’s trial being shared, along with novel platforms and autologous approaches for cell therapy in GBM.
With expert insights from:
Overcoming the Brain’s Immunosuppressive Environments with Cell Therapy Approaches for Breakthrough GBM Treatments
Following Kite Pharma and Gilead’s impressive breakthrough in a CAR-T treatment for Glioblastoma, cell therapy approaches are becoming a new source oh hope for the GBM field. This session will see data from Kite/Gileads’s trial being shared, along with novel platforms and autologous approaches for cell therapy in GBM.
With expert insights from:
- Ulrike Gerdemann, Principal Investigator & Physician Scientist, Dana-Faber Cancer Institute & Harvard Medical School
- Aaron Edwards, Co-Founder & Chief Executive Officer, KiraGen Bio
- Carlo Russo, Chief Medical Officer, Genenta Science
Navigating the Investment & Partnerships Landscape in GBM & Matchmaking Roundtables
Join Merck, Modifi Bio, Google Ventures, RA Capital Management, Brain Tumor Investment Fund and White Lion Capital to discuss key milestones, translatable models and biomerkaers that are prioritized by investors to mitigate the high risk nature of GBM drug development.
Network with:
- Carla Bauer, Director - Oncology Search & Evaluation, Business Development & Licensing, Merck & Co
- Ranjit Bindra, Founder, Modifi Bio
- Jonathan Pritz, Investment Director – Venture, RA Capital Management
- Yash Thukral, Managing Director, White Lion Capital
- John Higgins, Managing Director, Brain Tumour Investment Fund
- Sam Blackman, Entrepreneur-in-Residence, Google Ventures
Gain Exposure to Investors by Taking Part in the Pitch Slam
Our tech slam welcomes the opportunity for 4 biotechs eager to promote their technology to our investors through 15-minute presentations with a guaranteed audience of our investment and pharma business development speakers. Contact sponsor@hansonwade.com to learn more.
Explore the Innovative Use of AI in Reducing Development Time & Improving Trial Enrolment
Hear from how innovative applications of AI are reducing bench to bedside timelines and improving clinical experience for patients, practitioners, and families.
Hear from:
- Jason Binder, Head of Patient Experience, Pathos AI
- Panna Sharma, Chief Executive Officer & President, Lantern Pharma
Explore the Full Event Guide
- 90+ industry attendees
- 25+ World Class Speaker
- 6 deep-dive workshops, covering end-to-end drug development
- 8+ Hours on Networking
- The world’s only industry-led forum focussed on Glioblastoma drug development
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.